ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sucampo buys start-up Vtesse

by Ann M. Thayer
April 10, 2017 | APPEARED IN VOLUME 95, ISSUE 15

Sucampo Pharmaceuticals will pay $200 million in stock and cash to acquire Vtesse, a privately held firm focused on rare diseases. Launched in January 2015, Vtesse was the first spin-off from the Pfizer-backed orphan drug accelerator Cydan Development. Vtesse’s lead product is VTS-270, a mixture of 2-hydroxypropyl-β-cyclodextrins in Phase II/III trials for the ultrarare genetic disorder Niemann-Pick disease type C1 (NPC). After the acquisition closes, Vtesse’s former owners intend to put a portion of proceeds, to be matched by Sucampo, into a new NPC-related research foundation.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment